Zealand Pharma A/S (OTCMKTS:ZLDPF) Trading Down 2.3% – Here’s What Happened

Zealand Pharma A/S (OTCMKTS:ZLDPF) traded down 2.3% during trading on Wednesday . The stock traded as low as $115.00 and last traded at $115.00. 505 shares traded hands during mid-day trading, a decline of 75% from the average session volume of 1,987 shares. The stock had previously closed at $117.77.

Zealand Pharma A/S Trading Down 2.3 %

The company has a market cap of $5.92 billion, a price-to-earnings ratio of -63.19 and a beta of 0.95. The company has a debt-to-equity ratio of 0.03, a quick ratio of 35.57 and a current ratio of 35.57. The firm has a fifty day moving average price of $128.10 and a 200 day moving average price of $111.76.

Zealand Pharma A/S (OTCMKTS:ZLDPF) last posted its quarterly earnings results on Thursday, August 15th. The company reported ($0.67) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.61) by ($0.06). Zealand Pharma A/S had a negative net margin of 191.92% and a negative return on equity of 18.17%. The business had revenue of $4.93 million during the quarter, compared to the consensus estimate of $0.50 million. As a group, equities analysts predict that Zealand Pharma A/S will post -2.29 EPS for the current fiscal year.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.